Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder

April 16, 2023 · Benzinga

Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published in the acclaimed JAMA Oncology.

The open-label Phase 2 study tested psilocybin paired with psychological support in 30 patients with curable and incurable cancer. Participants were divided into cohorts of 3 to 4 and each was given a 25 mg single dose of COMPASS 

CMPS-0.10%+ Free Alerts’ synthetic psilocybin COMP360.

Dosing was done simultaneously on all patients, who were located in adjacent rooms open to a common space, in a one-on-one therapist/patient ratio. Group therapy was provided throughout one preparation and two integration sessions, which were supplemented by individual therapy.

Data from the study showed a sustained response in 80% of patients and 50% of patients in full remission of depressive symptoms, as measured on MADRS scores, from baseline to 8 weeks post-treatment. 

Self-reported measures of depressive symptoms supported the findings, with an average 48% reduction from baseline and a 53% decrease in depression severity.

Sunstone’s CEO and the study’s PI, Dr. Manish Agrawal said the trial is “the first of its kind,” conducted within a community hospital cancer center in groups and using a lower therapist-to-patient ratio than previous psilocybin therapy studies. 

“This approach has been shown to be effective in delivering a significant improvement in these patients’ depression symptoms and, if replicated in larger studies, could open the door to a wider and faster adoption of psilocybin therapy in the future,” Dr. Agrawal said.

Chief therapist Bill Richards, Ph.D. commented that although the number of study participants was small, the results from the open-label study add to the growing body of evidence on psilocybin therapy for mental distress and provides hope to cancer patients and their families of an effective treatment for depression associated with their condition which, he says, “impacts 1 in 4 people with cancer and often becomes a debilitating aspect of their diagnosis.” (Full Story)

In categories:Psychedelics Research
Next Post

April 19 Bicycle Day Celebrates The First LSD Trip

While most people in the cannabis industry are gearing up for the high holiday of April, 20 or 420, our good friends in the psychedelic industry have their own day of celebration. It’s called Bicycle Day and it falls on…
Previous Post

Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations

Clinical-stage biopharma company atai Life Sciences  ATAI-6.00%+ Free Alerts announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of proprietary R-ketamine, PCN-101. Open-label, the trial is set to assess safety, tolerability and pharmacokinetic profile of 60mg,…
Random Post

Virginia Election Forecast Predicts Democratic Wins In House And Senate, Which Could Lead To Legal Marijuana Sales

A new forecast of Virginia’s election predicts that Democrats are likely to win control of both chambers of the legislature on Tuesday—a result some advocates believe could open the door for lawmakers to legalize retail cannabis sales in the state. A…
Random Post

Small Trial Suggests DMT Can Improve Symptoms of Depression

A trial conducted by biotechnology company Small Pharma found that the psychedelic DMT could improve symptoms of depression when used in conjunction with therapy. In the study, which used intravenous DMT dosing, 14 participants out of 34 were in remission…
Random Post

New Missouri Cannabis Rules Require Testing Labs to Double-Check Each Other’s Work

New rules implemented in Missouri allow regulators to instruct the state’s certified cannabis testing laboratories to double check the work of other labs – an effort to cut down on so-called ‘lab shopping,’ the Missouri Independent reports. Under the regulations, the state…
Random Post

Federal Appeals Court Rules Against DEA In Psilocybin Rescheduling Lawsuit Brought By Doctor Who Wants To Give Psychedelic To Cancer Patients

A federal appeals court has ruled against the Drug Enforcement Administration (DEA) in a lawsuit over a Washington State doctor’s petition to reschedule psilocybin. The court said DEA failed to explain its reasoning when it denied the petition, and it ordered…